Abstract
Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and preclinical and clinical research with these agents to date is described.
Keywords: serotonin, antidepressants, neurotransmitters, inhibitors, clinical research, Triple-Action Hypothesis
Current Neuropharmacology
Title: Triple Reuptake Inhibitors: The Next Generation of Antidepressants
Volume: 6 Issue: 4
Author(s): David M. Marks, Chi-Un Pae and Ashwin A. Patkar
Affiliation:
Keywords: serotonin, antidepressants, neurotransmitters, inhibitors, clinical research, Triple-Action Hypothesis
Abstract: Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review explores limitations of presently available antidepressants and the history and premise behind the movement to devise triple reuptake inhibitors. The evidence for and against the claim that broader spectrum agents are more efficacious is discussed. Examples of triple reuptake inhibitors in development are compared, and preclinical and clinical research with these agents to date is described.
Export Options
About this article
Cite this article as:
Marks M. David, Pae Chi-Un and Patkar A. Ashwin, Triple Reuptake Inhibitors: The Next Generation of Antidepressants, Current Neuropharmacology 2008; 6 (4) . https://dx.doi.org/10.2174/157015908787386078
DOI https://dx.doi.org/10.2174/157015908787386078 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Eisenmenger Syndrome: Recent Advances in Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Progress of Imaging Agents for Parkinson’s Disease
Current Neuropharmacology Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA Low-Molecular Weight Heparins in Percutaneous Coronary Interventions: Current Concepts, Problems, and Perspectives
Current Pharmaceutical Design Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Impairment of Liver Glycogen Storage in the db/db Animal Model of Type 2 Diabetes: A Potential Target for Future Therapeutics?
Current Drug Targets Angiotensin II in Type 2 Diabetes Mellitus
Current Protein & Peptide Science Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms
Current Topics in Medicinal Chemistry Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets An Update on Natural Occurrence and Biological Activity of Chromones
Current Medicinal Chemistry The Role of Endothelin System in Cardiovascular Disease and the Potential Therapeutic Perspectives of its Inhibition
Current Topics in Medicinal Chemistry Anti-Diabetic Compounds and their Patent Information: An Update
Recent Patents on Inflammation & Allergy Drug Discovery Salen Mn Complexes are Superoxide Dismutase/Catalase Mimetics that Protect the Mitochondria
Current Inorganic Chemistry (Discontinued) Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment
Current Alzheimer Research Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Antihypertensive Properties of Angiotensin-Converting Enzyme Inhibitors (ACEI) Independent of the Renin-Angiotensin System
Current Hypertension Reviews Bioactive Compounds of <i>Polygonatum sibiricum</i> - Therapeutic Effect and Biological Activity
Endocrine, Metabolic & Immune Disorders - Drug Targets